InvestSMART

Prescient Therapeutics Limited (ASX:PTX)

ALERT: Price-sensitive ASX Announcement for PTX
Current share price for PTX : $0.065 -0.002 (-2.99%)+
Announcement
Release
26 Aug 2026 8:57AM
Price at Release
$0.067
Full Release
download
Summary
Prescient Therapeutics Limited (PTX), an Australian clinical-stage oncology company, has initiated a Share Purchase Plan (SPP) to raise up to $7 million to support the development of its cancer treatment, PTX-100. The SPP allows eligible shareholders to purchase additional shares at a discounted price, aiming to fund the advancement of PTX-100 through clinical trials and towards regulatory approval. The funds will also support general corporate activities and potential pipeline opportunities. The initiative follows a year of significant progress in clinical trials and aims to strengthen PTX's position in the biotechnology sector.
Key Points
  • Prescient Therapeutics opens a Share Purchase Plan to raise $7 million.
  • Funds are aimed at advancing the cancer treatment PTX-100.
  • SPP offers shares at a 9.7% discount to the closing price.
  • Eligible shareholders can purchase up to $30,000 in shares.
  • Proceeds will support clinical trials and regulatory approvals.
  • The SPP is available to shareholders in Australia and New Zealand.
  • Funds will also support business development and potential new opportunities.
  • The SPP runs until 8 September 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.